MedTrace Logo

Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer

NCT01146340 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-10-04

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (40 Gy / 5 fractions / 29 days) for the treatment of low- and intermediate-risk prostate cancer.

Conditions

Interventions

RADIATION

Hypofractionated radiotherapy

40 Gy / 5 fractions / 29 days

Sponsors & Collaborators

  • Canadian Association of Radiation Oncology

    collaborator INDUSTRY

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Andrew Loblaw, MD · Sunnybrook Health Sciences Centre

  • Harvey Quon, MD · Sunnybrook Health Sciences Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01146340 on ClinicalTrials.gov